Document is current
Any future updates will be listed below
-
Authors
Sahin, Ugur https://orcid.org/0000-0003-0363-1564
Oehm, Petra https://orcid.org/0000-0002-1086-2726
Derhovanessian, Evelyna
Jabulowsky, Robert A.
Vormehr, Mathias https://orcid.org/0000-0001-7788-3380
Gold, Maike
Maurus, Daniel
Schwarck-Kokarakis, Doreen
Kuhn, Andreas N.
Omokoko, Tana
Kranz, Lena M.
Diken, Mustafa
Kreiter, Sebastian
Haas, Heinrich
Attig, Sebastian
Rae, Richard
Cuk, Katarina
Kemmer-Brück, Alexandra
Breitkreuz, Andrea
Tolliver, Claudia
Caspar, Janina
Quinkhardt, Juliane
Hebich, Lisa
Stein, Malte
Hohberger, Alexander
Vogler, Isabel
Liebig, Inga
Renken, Stephanie
Sikorski, Julian
Leierer, Melanie
Müller, Verena
Mitzel-Rink, Heidrun
Miederer, Matthias https://orcid.org/0000-0001-5075-5995
Huber, Christoph
Grabbe, Stephan
Utikal, Jochen
Pinter, Andreas
Kaufmann, Roland
Hassel, Jessica C.
Loquai, Carmen
Türeci, Özlem
- License Information
-
More Information
Article History
Received: 23 October 2019
Accepted: 27 April 2020
First Online: 29 July 2020
Competing interests
: U.S., R.A.J., D.S.-K., A.N.K., L.M.K., M.D., S.K., H.H. and Ö.T. are inventors on patents related to the RNA-LPX vaccine technology. Some of the authors have securities from BioNTech.
